Why Attend
With key CPG brands launching skin microbiome focused brands over the last few years, skin microbiome is entering the mainstream of the beauty and personal care industry. The field is still in a nascent stage, but as next generation sequencing techniques and big data analysis improve, a galaxy of new information is set to be uncovered. With new regulation coming in to hold back the use of unsubstantiated claims, with high profile cases including Clariant, understanding the research and governing of this space has never been more important.
Join us this December to find out about the latest R&D and regulation that is shaping the direction for skin microbiome product development with our expert speaker faculty of key industry representatives and academics.
"An amazing event, bringing you close to industrial representatives and providing you with the opportunity to not only understand what companies are doing but also to talk with them in engage in discussion. What a great networking opportunity" - KU Leuven
Who will be there
Meet Industry Leading Experts in:
- Independent Beauty and Personal Care Brands
- Biotech Companies
- Academic Researchers and Dermatologists
- Multinational Beauty & Personal Care Brands and Multinational Pharmaceutical Companies
- Cosmetic Formulators, Strain Manufacturers, Ingredients Suppliers, Packaging Manufacturers and Sequencing companies
- Regulatory Experts and Consumer Trend Analysts
- Retailers and Distributors
Advisory Board
Jay Tiesman
Dr. Jay Tiesman is a Principal Scientist in the Global Biotechnology Division of The Procter & Gamble Company in Cincinnati, Ohio, USA. He is the Genomics Group Leader and a Corporate Technology Entrepreneur charged with helping to identify novel biotechnology innovations worldwide to address key needs for P&G. Since joining P&G in 1993, he has been actively involved in developing genomics capabilities within the Company. He has been particularly interested in the use of genomics to gain insight into epithelial cell biology.
Before joining P&G, he completed postdoctoral training in the laboratory of Dr. Charlie Hart at ZymoGenetics, Inc. in Seattle, Washington. At ZymoGenetics, he pursued research in the field of growth factor signal transduction associated with wound healing and tissue remodeling. He obtained his Ph.D. in Pathology from the University of Nebraska Medical Center in Omaha, Nebraska. In Omaha, he worked in the Laboratory of Dr. Angie Rizzino at the Eppley Cancer Institute, delineating the roles and impact of growth factors on embryonic development. Before joining Dr. Rizzino, he obtained Bachelor degrees in Philosophy and Biology at Creighton University in Omaha.
Dr. Tiesman was an early adopter of microarray technology, having worked in the field since 1997. He is an acknowledged microarray expert and has published over 35 articles, two of which have earned Publication of the Year honors. He also speaks extensively at international meetings on the topic of microarray experimental design and is listed on over 85 presentations. He collaborates extensively with scientists in academia and the biotechnology industry and is a member of several academic/governmental/industrial organizations, including the Association of Biomedical Resource Facilities Microarray Research Group (ABRF-MARG), the Association of Molecular Pathology (AMP), and the Society for Investigative Dermatology (SID); as well as the Scientific Advisory Board of NuGEN Technologies, Inc.
Kim Capone
Sarah De Szalay
Larry Weiss
Trevor Steyn
Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.
Ingmar Claes, PhD
Ingmar studied bioscience engineering at the University of Leuven, graduated in 2007 and obtained a PhD in cell and gene technology in 2011. He has an expertise in the field of probiotics, its molecular mechanisms and the topical application of these beneficial bacteria to restore the human microbiome. As bioengineer and microbiologist, he feels that it is important to translate this scientific research into daily products from which people at home and the community can benefit.
In the context of YUN, he is closely working together with the Department of Bioscience Engineering of the University of Antwerp, the Lab of Applied Microbiology and Biotechnology of prof. Sarah Lebeer, the Lab of Pharmaceutical Technology and Biopharmacy of prof. Filip Kiekens, prof. dr. Julien Lambert (dermatology) and dr. Gilbert Donders (gynaecology, the University Hospital of Antwerp).
He has experience with leadership in multiple R&D projects and he held a managing role in YUN’s R&D projects of the Flemish Institute for the Promotion of Scientific and Technological Research in Industry (VLAIO). YUN’s current range of probiotic products and therapies were developed under his supervision.
Dr Chris Callewaert
Chris received his PhD from Ghent University in Belgium. He is now a postdoctoral research fellow in the Knight lab at the University of California, San Diego. He investigates body odor and the characteristics of the bacteria living in the armpits, skin, clothes, washing machines and homes. He is the first to undertake bacterial transplants to solve underarm body odour.
Audrey Gueniche Ph.D
Audrey GUENICHE obtained her Pharmacist degree and her PhD degree in skin biology more than 23 years ago. She is an expert on immunology and microbiology. Her main expertise is on skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a senior clinical expert in LOREAL RESEARCH. She has a complete experience from the actives through vitro evaluations/ preclinical studies to clinical trials. Her passion is to always reinvent evaluation and find new fields of area in term of actives to promote.
She has published over 110 papers in peer-reviewed journals, 5 chapters in books, 2 specials issues in journal where she was the invited editor. She presented in over 80 international congresses and additionally she was personally invited to give more than 35 keynote lectures.
Erwan Peltier
Cath O’Neill
OUR 2021 PARTNERS
Gold Partner
Biose Industrie
Website: https://www.biose.com/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
Silver Partners
Clinical Microbiomics
Website: www.clinical-microbiomics.com
Our inner ecology – that delicate microbial ecosystem known as the microbiome – is the new frontier in human health. At Clinical Microbiomics, we exist to untangle its complexity in search of mechanisms that impact health and disease.
Identifying and understanding those mechanisms is like looking for a needle in a haystack and demands a truly interdisciplinary approach to microbiome science. Innovating at the forefront of the field, our team of leading scientists creates breakthrough bioinformatics tools and analytical concepts that set new standards for understanding and influencing the microbiome.
Clinical Microbiomics is proud to partner with researchers from the world’s most prominent academic institutions and leading biotech, consumer health and pharma companies. Operating as an extension of their research organizations, we work broader, analyze deeper, and connect the dots to help find the answers needed to impact health and disease.
Quay Pharma
Website: https://www.quaypharma.com
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Bayer
Website: https://www.bayer.com/en/
Bayer is a recognized leader in the area of women’s healthcare, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. Today, Bayer’s research and development efforts focus on finding new treatment options for menopause as well as gynecological diseases and includes several compounds in various stages of pre-clinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to alter the way that gynecological diseases are treated. Additionally, Bayer intends to provide 100 million women in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.
Bacthera
Website: https://www.bacthera.com/
Bacthera is a Danish/Swiss-based one-stop CDMO in the field of LBP’s, with the overall goal to enable the entire industry to further flourish by introducing industry changing innovations.
From small start-up’s to globally operating pharmaceutical companies, we support our clients developing analytical and manufacturing processes of their strains. With our long experience in handling bacteria in DS and DP production, we can offer tailor-made development and large-scale commercial solutions. Within our facilities, we can handle:
- Strictly and facultative anaerobes
- BSL1/2 categorized strains
- GMO’s
Our customers benefit from background technologies and GMP manufacturing know-how that originate from our mother companies Chr. Hansen & Lonza. In addition, Bacthera’s process expertise, enabling innovations and our world-class analytical services will contribute to our customer’s successful development of their LBP.
LabSkin
Website: https://www.labskin.co.uk/
Labskin is a world-leading platform that has been producing lab-grown human skin for 15 years and using it to test cosmetic and skin health products for the world’s leading brands. Labskin is the only commercially available full thickness human skin model that naturally mimics the skin's microbiome.
In 2021, we launched Skin Trust Club which combined our deep science knowledge with our AI expertise in solving an unmet consumer need. Skin Trust Clun is a skin health tracking app that provides personalised skin care suggestions based on testing your unique skin microbiome.
Zymo Research
Website: https://www.zymoresearch.com/
Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that "the beauty of science is to make things simple.
Baseclear
Website: https://www.baseclear.com/
As genomics experts and through sustainable partnerships BaseClear offers consultancy and technological expertise to accelerate the understanding and use of microorganisms. BaseClear, located in the leading biomedical hotspot in Europe, offers a complete range of microbial genomics services, including metagenomics, microbiome analysis and microbial strain assessment for regulatory approval.
Senior Event Partner
COPAN
Website: https://www.copangroup.com/
Copan is dedicated to developing and providing high quality and cutting-edge biological sample collection products for infectious diseases, forensic, human genomics and environmental applications, along with automated workflow solutions.
To offer an efficient nucleic acid collection for microbiome analysis purposes, we specifically designed our new product SMART-eNAT®. Provided with the innovative post-collection activation system, SMART-eNAT® inhibits microbial growth and DNA degradation, ensuring safe transport for prolonged periods at ambient temperature and an unbiased microbiome profiling.
Today Copan is still eager to continue this innovation, providing quality products, customized services and prime solutions to improve the health and wellness of patients. Visit our booth to learn more about us!
Event Partner
Atlantia Clinical Trials
Website: https://atlantiaclinicaltrials.com/
Please visit our website for more information.ProDigest
Website: www.prodigest.eu
ProDigest is a contract research provider with broad range of solutions for in vitro gastrointestinal simulation, both for the upper and the lower gastrointestinal tract, ranging from high throughput screening to in depth investigation of the mode of action and site of effect.
For example, we assist your product development by building up essential know-how in the field of gastrointestinal transit, bioavailability, digestion, metabolism, microbiome, immune modulation and efficacy of probiotics, prebiotics, functional ingredients, and pharmaceuticals, in relation to their fate and function in the body.
Our long-standing experience and expertise in studying the gastrointestinal processes at your service!
Phage Consultants
Website: https://phageconsultants.com/
Please visit our website for more information.DNA Genotek Inc.
Website: www.dnagenotek.com
DNA Genotek Inc. is a subsidiary of OraSure Technologies, Inc. working to provide high-quality microbial sample collection products and comprehensive services for sample processing, sequencing, and bioinformatic analysis. DNA Genotek’s OMNIgene product line immediately stabilizes microbiota samples at the point of collection, ensuring an unbiased ‘snapshot’ of the microbial community. Self-collection kits for stool, oral, skin, vaginal and animal sampling are available.
OUR 2021 SPEAKER FACULTY
Matthew Hardman
Edith Hessel
Dr Gregory Gloor
Soeren Kjaerulff phd
Dr Joey Shepherd
Larry Weiss
Dr Julie Thornton
Carla Oates
Geoff Briggs
Trevor Steyn
Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.
Assaf Oron
Elsa Jungman
Dr Chris Callewaert
Chris received his PhD from Ghent University in Belgium. He is now a postdoctoral research fellow in the Knight lab at the University of California, San Diego. He investigates body odor and the characteristics of the bacteria living in the armpits, skin, clothes, washing machines and homes. He is the first to undertake bacterial transplants to solve underarm body odour.
Dr Cath O'Neill
Audrey Gueniche Ph.D
Audrey GUENICHE obtained her Pharmacist degree and her PhD degree in skin biology more than 23 years ago. She is an expert on immunology and microbiology. Her main expertise is on skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a senior clinical expert in LOREAL RESEARCH. She has a complete experience from the actives through vitro evaluations/ preclinical studies to clinical trials. Her passion is to always reinvent evaluation and find new fields of area in term of actives to promote.
She has published over 110 papers in peer-reviewed journals, 5 chapters in books, 2 specials issues in journal where she was the invited editor. She presented in over 80 international congresses and additionally she was personally invited to give more than 35 keynote lectures.
Ingmar Claes, PhD
Ingmar studied bioscience engineering at the University of Leuven, graduated in 2007 and obtained a PhD in cell and gene technology in 2011. He has an expertise in the field of probiotics, its molecular mechanisms and the topical application of these beneficial bacteria to restore the human microbiome. As bioengineer and microbiologist, he feels that it is important to translate this scientific research into daily products from which people at home and the community can benefit.
In the context of YUN, he is closely working together with the Department of Bioscience Engineering of the University of Antwerp, the Lab of Applied Microbiology and Biotechnology of prof. Sarah Lebeer, the Lab of Pharmaceutical Technology and Biopharmacy of prof. Filip Kiekens, prof. dr. Julien Lambert (dermatology) and dr. Gilbert Donders (gynaecology, the University Hospital of Antwerp).
He has experience with leadership in multiple R&D projects and he held a managing role in YUN’s R&D projects of the Flemish Institute for the Promotion of Scientific and Technological Research in Industry (VLAIO). YUN’s current range of probiotic products and therapies were developed under his supervision.
Bernhard Paetzold Ph.D
Bernhard completed his PhD in synthetic biology, working together in collaboration with the pharmaceutical industry to engineer bacteria as a living pill. He is a scientific co-founder of S-Biomedic, and is leading the research and product development.
His passion is understanding the complex interplay of the bacterial communities that live within and on us. He is fascinated by the untouched potential of active compounds that are naturally produced everyday right on our own skin.
Tom Dawson
Niels Verhulst
Niels acquired his PhD at Wageningen University, The Netherlands and is now a senior researcher at the University of Zürich leading a group of scientists working on the behavioural ecology of mosquitoes.
He studies how skin microbial volatiles influence the attractiveness of humans and animals to mosquitoes. His goal is to develop novel skin bacterial based products that can reduce mosquito bites and thereby pathogen transmission.
Hasti Nazem
Hasti is part of the founding team of Kindra, leading product development and education. Kindra is developing innovative estrogen-free solutions targeting the top pain points of the 34+ symptoms of menopause. With nearly 10 years of experience at the intersection of life sciences, health and wellness, and consumer brand building, Hasti integrates targeted product formulation development with cutting edge technical advancements. Her deep scientific communications experience helps to empower consumers to better understand their health, and bridge gaps often overlooked in women's health. Hasti's work has been featured in has been featured in The New York Times, Forbes.com, (O) Oprah Magazine, Harper's Bazaar, Women's Health Magazine, and in healthcare public affairs and pharmaceutical trade association publications.
Erwan Peltier
Sarah De Szalay
David Caballero-Lima
David received his undergraduate degree in Biology and his PhD in Biomedical Sciences from the Universidad de Extremadura in Spain. David took postdoctoral research positions at the University of Sheffield and the University of Manchester, with both roles focusing on studying human/pathogen interaction via tissue models and obtaining a greater understanding in the regulation of the cell cycle and vesicle transportation during morphological changes. In addition he was involved in the development of point-of-care diagnostic devices for diseases such as fungal and bacterial keratitis and novel antifungal discovery.
David was initially Services Manager at Labskin, responsible for all microbiology work and service projects, bringing his 18 years’ experience working with microbiology and host-pathogen interactions.
As Head of R&D, David now leads the research department, focusing on the development of new methods for studying the native skin microflora, prebiotic, probiotics and antimicrobial effects of ingredients and formulation for pharmaceutical and cosmeceutical studies. He is also the scientific lead for the development of Labskin new consumers service; Skin Trust Club, a new concept of personalised skin care based on the analysis of the skin microbiome. David is a key collaborator on international research bids, as a peer with leading international experts from academia and industry.
Colin O'Sullivan
Colin O’Sullivan joined the Deepverge team as Chief Information Officer (CIO) following the acquisition of Rinocloud Ltd. Colin is responsible for creating an information technology strategy targeted at the Deepverge growth opportunities. Colin is a global, talented, results-driven Technology leader with versatile, cross-platform experience in Digital Strategy, Medical and Science Applications, Enterprise Applications, Cloud Computing, Mobile Enablement, Business Intelligence, Artificial Intelligence, IT Operations, Customer Experience and DevOps for diverse client industries.
Colin earned a Bachelor of Science degree at Cork Institute of Technology. As an undergraduate Colin demonstrated his early passion for technology with the winning of web design awards while leading his own digital agency Keynet Ltd. Colin went on to earn a Master of Science degree at Trinity College Dublin specialising in Ubiquitous Computing and Distributed Systems.
Colin relocated to Sydney Australia to take up strategic technology roles with responsibilities across the Asia Pacific region in a wide number of industries including Medical, Travel, Education and Science.
More recently as the Group Chief Information Officer at the Australian Medical Association (AMA) Colin developed the technology strategy for both the membership organisation, publishing and commercial subsidiaries across Australia. Returning to Ireland from Australia Colin took up the role of Chief Information Officer at Rinocloud Ltd. Colin was responsible for development of the new product strategies with a focus on scientific data Artificial Intelligence (AI) platforms. With over a decade of experience in Executive Management roles across the globe and over 20 years experience delivering innovative technology solutions Colin has now brought his skills to the Deepverge Senior Management team.
Tuval Ben-Yehezkel, PhD
Tuval Ben-Yehezkel is a scientist-entrepreneur focused on applied genomics and synthetic biology. Authored key patents, publications and book chapters in synthetic biology and genomics. Founded and secured $15.3M in funding for two biotech start-up companies.
Agenda
We're thrilled to share the programme for the 6th Annual Microbiome Connect: Skin Europe with you and couldn't be more excited to welcome you back face-to-face in Amsterdam this December! Download the agenda on the right hand side to find out more.
Here’s a sneak peek of some key takeaways:
- Hear from the leading experts in the microbiome field to further understand their pipelines and clinical data
- Learn about regulatory pathways to develop commercially viable products in the skin microbiome space
- Discover and apply the newest techniques in personalisation of microbiome skincare, with focuses on data collection and sampling
- Uncover the most innovative technological advances across a range of areas, including AI and sequencing for use in R&D translation
- As ingestibles become an increasing feature of microbiome care, learn about the newest developments and research from experts in the field for further portfolio expansion
- Identify key modalities for limiting the impact of dysbiosis through phage, LBP, prebiotics and more
To get an idea what a face-to-face conference with us looks like, check out a video of what we were up to in previous years.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
— —
- Multinationals, Pharma, Beauty & Personal Care Companies€899VIRTUAL Standard Pricing
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
